Re: ‘ESCMID COVID-19 living guidelines: drug treatment and clinical management’ by Bartoletti et al

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease

“…Concern about use of remdesivir has been previously raised following observation coming from real world data [ 36 , 37 ]. However, in the PINETREE trial patients receiving remdesivir did not experience a higher rate of severe adverse events and other adverse events when compared with controls ( Table 4 ).…”

A bit of a cough, tired, not very resilient – is that already Long-COVID? Perceptions and experiences of GPs with Long COVID in year three of the pandemic. A qualitative study in Austria.

“…Most patients with self-reported long COVID were not hospitalized due to their SARS-CoV-2 infection and only had mild symptoms of the infection itself. New studies indicate that people at higher risk are women, people aged 35 to 69, socioeconomically deprived people, people working in social care, people belonging to ethnic minorities, and people with other activity-limiting illnesses [4,19,20]. Studies also found that long COVID impacts children of all ages [4,9,14,21].…”

“…Symptoms affect many different organs and physiological pathways, can be interrelated and all need to be studied more profoundly. The symptoms can be clustered into systems: they can affect neurological and cognitive, cardiovascular, gastrointestinal, dermatological and respiratory/pulmonary systems [4,5,[14][15][16]19]. Impacts can also be on the reproductive system with effects, for example, on menstruation, yet sex-speci c pathophysiology has to be studied in more detail.…”

“…Thus, long-COVID patients are usually directed towards their family physician who is responsible for managing and coordinating long-COVID -referring to specialists and laboratories for tests as well as referring to several other health professionals for treatment, such as physio-, ergo-or psychotherapists, dieticiants and others. Therefore, the Austrian Society of General Practice (Österreichische Gesellschaft für Allgemein-und Familienmedizin, ÖGAM) worked out an S1 Long-Covid guideline together with seven other Austrian medical societies that was published in December 2021 [20] and has been updated in 2023 [19]. It is directed towards primary health services in Austria and is supposed to be a helpful and practical tool that is also available via an easy-to-use webtool.…”

Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients

“…We have read with great interest the recent comment by dr. Dauby considering cardiovascular side-effects of remdesivir [ 1 ] that might question its role in the treatment of severe COVID-19 patients [ 2 ]. At the moment bradycardia is considered to be most frequent cardiovascular side-effect of remdesivir and occurs due to undisclosed mechanism.…”